Study

Alzheimer’s Neurotransmitter Study

A new oral medication

For those with mild-to-moderate Alhzeimer's disease

Patients with mild to moderate Alzheimer’s disease often have negative changes in how efficiently their bodies process dopamine, a neurotransmitter that helps nerve cells send messages to each other. This can lead to adverse changes in personality, mood, and behavior.

This investigational drug enhances the body’s ability to utilize dopamine. In theory, this may boost dopamine’s effectiveness in someone with Alzheimer’s. The study will look at whether the drug is a safe and effective treatment to improve thinking (cognition), memory, and executive function in patients with mild-to-moderate Alzheimer’s disease.

 

Who is eligible?

You may qualify for this study if:

  • You are 50-80 years old
  • You have gradual & progressive decline in memory function for more than 6 months.
  • You have historical evidence of Alzheimer's disease

Sign Up

Schedule Your Assessment

Sign up for an initial assessment (called a “prescreen”), and we'll give you a call. One of our professional medical staff will answer your questions and give you more information about Charter Research prior to an in-office visit.

Get More Information

Your contact information

Do you live in Central Florida?

Preferred Charter Research location

I would like to receive the Charter Research newsletter.

I would like to receive text messages from Charter Research for communication purposes.

Comments (not required)

This field is for validation purposes and should be left unchanged.

Locations supporting this study

Select Location: